Neurolixis is a science-driven company and places high priority on characterizing its drug development candidates (NLX-112 and NLX-101) in rigorously-conducted pharmacological studies. NLX-112 was previously known as F13640 (befiradol) whereas NLX-101 was previously known as F15599.

For a complete list of publications on NLX-112 and NLX-101, see the PubMed database.

For abstracts (and some free PDFs) of selected publications see the links below.